Add to ORKGPomalidomide: the new immunomodulatory agent for the treatment of multiple myelom
Abstract Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating cl...
Th e design of innovative, more eff ective, less toxic therapy of multiple myeloma (MM) is emerging ...
Primary CNS lymphoma carries a poor prognosis. Novel therapeutic agents are urgently needed. Pomalid...
International audiencePomalidomide, a very potent member of the immunomodulatory drug family, is con...
National audienceOnce characterized by a very poor outcome, multiple myeloma (MM) now has a signific...
Introduction: Multiple myeloma patients who are refractory to lenalidomide and bortezomib have a dis...
Once characterized by a very poor outcome, multiple myeloma (MM) now has a significantly prolonged s...
In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatmen...
The design of innovative, more effective, less toxic therapy of multiple myeloma (MM) is emerging in...
Currently, there has been a marked increase in the number of opportunities for relapsed and refracto...
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune...
Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and...
The treatment of multiple myeloma has evolved significantly over the past 2 decades due to the use o...
Thalidomide-based Immunomodulatory Drugs (IMiDs®), including lenalidomide and pomalidomide, are effe...
In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatmen...
Abstract Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating cl...
Th e design of innovative, more eff ective, less toxic therapy of multiple myeloma (MM) is emerging ...
Primary CNS lymphoma carries a poor prognosis. Novel therapeutic agents are urgently needed. Pomalid...
International audiencePomalidomide, a very potent member of the immunomodulatory drug family, is con...
National audienceOnce characterized by a very poor outcome, multiple myeloma (MM) now has a signific...
Introduction: Multiple myeloma patients who are refractory to lenalidomide and bortezomib have a dis...
Once characterized by a very poor outcome, multiple myeloma (MM) now has a significantly prolonged s...
In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatmen...
The design of innovative, more effective, less toxic therapy of multiple myeloma (MM) is emerging in...
Currently, there has been a marked increase in the number of opportunities for relapsed and refracto...
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune...
Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and...
The treatment of multiple myeloma has evolved significantly over the past 2 decades due to the use o...
Thalidomide-based Immunomodulatory Drugs (IMiDs®), including lenalidomide and pomalidomide, are effe...
In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatmen...
Abstract Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating cl...
Th e design of innovative, more eff ective, less toxic therapy of multiple myeloma (MM) is emerging ...
Primary CNS lymphoma carries a poor prognosis. Novel therapeutic agents are urgently needed. Pomalid...